EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Pathological concordance rate and outcomes by subtype in advanced papillary renal cell carcinoma

Abhishek Tripathi, Catherine M Tangen, Melissa Plets, Xiaochen Li, Maria Tretiakova, Peter A Humphrey, Adebowale Adeniran, Pedro C Barata, Shuchi Gulati, Cristiane D Bergerot iD, Deepak K Pruthi iD, Ian M Thompson und 4 weitere

BJU International · 2024

DOI: 10.1111/bju.16403 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift BJU International, 2024. Verfasst von Abhishek Tripathi und 15 weiteren Autor:innen. Beteiligte Einrichtung: City of Hope Comprehensive Cancer Center, Duarte, CA, USA. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit nennt 16 Literaturangaben. Gefördert von: Exelixis, AstraZeneca, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate the clinical significance of subtyping (type 1 vs 2) of papillary renal cell carcinoma (PRCC) in patients treated with targeted therapy, as well as the concordance, sensitivity and positive predictive value (PPV) of local review pathology review.

Methods

Patients with advanced refractory PRCC were randomised to receive sunitinib or cabozantinib, crizotinib or savolitinib, stratified by PRCC subtype (type 1, type 2, or not otherwise specified [NOS]/mixed) by local review. Central review was retrospectively conducted by three expert genitourinary pathologists who independently reviewed cases. The sensitivity and PPV of local review were estimated and outcomes [objective response rate (ORR), progression‐free survival (PFS)] were summarised for treatment groups stratified by subtypes by central review.

Results

Amongst the 147 patients reviewed, the prevalence of individual subtypes varied by local or central review (type 1: 17.7% vs 29.3%; type 2: 53.1% vs 45.6%; NOS/mixed: 29.3% vs 25.2%), respectively. Individual cases were frequently reclassified and local pathology review demonstrated low sensitivity (type 1: 48%, 95% confidence interval [CI] 33, 65; type 2: 67%, 95% CI 55, 78; NOS/mixed: 43%, 95% CI 27, 61). The PPVs of local review were 80%, 57.7% and 37% for type 1, 2 and NOS/mixed, respectively. Compared to sunitinib, cabozantinib demonstrated improved PFS for both type 1 and type 2 PRCC subgroups (7.4 vs 9.0 and 2.9 vs 5.6 months, respectfully) as well as higher ORR.

Conclusions

The PRCC subtype assignment did not identify a subset of patients with greater clinical benefit from cabozantinib, with significant discordance between local and central review. Our findings confirm the limited clinical value of pathological subtyping of metastatic PRCC, in line with the recent World Health Organisation 2022 guidelines. Patient summary In this study, categorising papillary renal cell carcinoma into type 1 or 2 subtypes showed limited concordance between central and local pathological review and did not enrich for patients more likely to benefit from cabozantinib in the S1500 PAPMET trial.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellKidney NeoplasmsHumansMaleFemaleMiddle AgedAgedRetrospective StudiesTreatment OutcomeAdultSunitinibAnilidesAntineoplastic AgentsPyridines

Stichwörter der Autor:innen

cabozantinibpapillary RCCrenal cell carcinomasunitinibtargeted therapytype 1type 2

Substanzen

SunitinibAnilidesAntineoplastic AgentsPyridinescabozantinib

Autor:innen und Institutionen

  • City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
  • SWOG Statistics and Data Management Center, Seattle, WA, USA.
  • Department of Biostatistics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
  • University of Washington, Seattle, WA, USA.
  • Yale University, New Haven, CT, USA.
  • University Hospitals Seidman Cancer Center, Cleveland, OH, USA.

ORCID-Profile: Cristiane D Bergerot, Deepak K Pruthi, Brian M Shuch

Förderung

  • Exelixis
  • AstraZeneca
  • NCI NIH HHS
  • Pfizer
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Tripathi, A., Tangen, C. M., Plets, M., Li, X., Tretiakova, M., Humphrey, P. A., Adeniran, A., Barata, P. C., Gulati, S., Bergerot, C. D., Pruthi, D. K., Thompson, I. M., Lara, P. N., Lerner, S. P., Pal, S. K., & Shuch, B. M. (2024). Pathological concordance rate and outcomes by subtype in advanced papillary renal cell carcinoma. BJU International. https://doi.org/10.1111/bju.16403

Vancouver

Tripathi A, Tangen CM, Plets M, Li X, Tretiakova M, Humphrey PA, et al. Pathological concordance rate and outcomes by subtype in advanced papillary renal cell carcinoma. BJU International. 2024. doi:10.1111/bju.16403

BibTeX
@article{Tripathi2024,
  author = {Tripathi, Abhishek and Tangen, Catherine M and Plets, Melissa and Li, Xiaochen and Tretiakova, Maria and Humphrey, Peter A and Adeniran, Adebowale and Barata, Pedro C and Gulati, Shuchi and Bergerot, Cristiane D and Pruthi, Deepak K and Thompson, Ian M and Lara, Primo N and Lerner, Seth P and Pal, Sumanta K and Shuch, Brian M},
  title = {Pathological concordance rate and outcomes by subtype in advanced papillary renal cell carcinoma},
  journal = {BJU International},
  year = {2024},
  doi = {10.1111/bju.16403}
}
Kostenlos starten →